A. Tavernaro

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

M. Buyse, R. Ramlau, E. Stoelben, 2011, The Lancet. Oncology.

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

E. Felip, J. Adam, A. Szczesna, 2016, The Lancet. Oncology.

Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.

J. Nemunaitis, E. Felip, L. Crinò, 2015 .

Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010.

R. Ramlau, J. Limacher, E. Quoix, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

63MO TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV)+ malignancies

J. Limacher, O. Lantz, O. Capitain, 2020 .

UV light selectively coinduces supply pathways from primary metabolism and flavonoid secondary product formation in parsley.

I. Somssich, E. Logemann, K. Hahlbrock, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers.

J. Limacher, O. Lantz, E. Piaggio, 2023, European journal of cancer.